Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects

Acta Biomaterialia

Volumn 10, Issue 3, 2014, Pages 1392-1402

  Song, Wantong ^a   Tang, Zhaohui ^a   Li, Mingqiang ^a,d   Lv, Shixian ^a,d   Sun, Hai ^a   Deng, Mingxiao ^b   Liu, Huaiyu ^c   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b NORTHEAST NORMAL UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Cisplatin; Combination chemotherapy; Paclitaxel; Polypeptide

Indexed keywords

AMINO ACIDS; BIOLOGICAL ORGANS; CELL CULTURE; CHELATION; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; POLYETHYLENE GLYCOLS; TARGETED DRUG DELIVERY; TUMORS;

CIS-PLATIN; CISPLATIN; COMBINATION CHEMOTHERAPY; L-PHENYLALANINE; METHOXY; PACLITAXEL; POLY(LGLUTAMIC ACID); POLY-L-GLUTAMIC ACIDS; SIDE EFFECT; TRIBLOCK-COPOLYMERS;

MICELLES;

CISPLATIN; COPOLYMER; PACLITAXEL; POLY(ETHYLENE GLYCOL) BETA POLY(GLUTAMIC ACID) BETA POLY(PHENYLALANINE); POLYPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTAMIC ACID; MACROGOL DERIVATIVE; MICELLE; MONOMETHOXYPOLYETHYLENE GLYCOL-GLUTAMIC ACID; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHELATION; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CELL DEATH; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; ENDOCYTOSIS; IC50; IMMUNOHISTOCHEMISTRY; NUDE MOUSE; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; ENDOCYTOSIS; GLUTAMIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; PACLITAXEL; PEPTIDES; POLYETHYLENE GLYCOLS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; TUMOR BURDEN;

EID: 84895071925     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2013.11.026     Document Type: Article

References (43)

1. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 2006 219 234
2. T. Boulikas, and M. Vougiouka Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (Review) Oncol Rep 11 2004 559 595
3. T. Shoji, E. Takatori, H. Omi, S. Kumagai, A. Yoshizaki, and Y. Yokoyama et al. Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study) Int J Gynecol Cancer 21 2011 44 50
4. Y. Patil, T. Sadhukha, L. Ma, and J. Panyam Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance J Controlled Release 136 2009 21 29
5. J. Lehar, A.S. Krueger, W. Avery, A.M. Heilbut, L.M. Johansen, and E.R. Price et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity Nat Biotechnol 27 2009 659 666
6. T. Liu, Y.F. Zhang, and S.Y. Liu Drug and plasmid DNA co-delivery nanocarriers based on abctype polypeptide hybrid miktoarm star copolymers Chin J Polym Sci 31 2013 924 937
7. Y.G. Wang, T.Y. Yang, X. Wang, W.B. Dai, J.C. Wang, and X.A. Zhang et al. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system J Controlled Release 149 2011 299 306
8. G.C. Huang, S.Y. Liu, M.H. Lin, Y.Y. Kuo, and Y.C. Liu The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma Jpn J Clin Oncol 34 2004 499 504
9. A.P. Jekunen, R.D. Christen, D.R. Shalinsky, and S.B. Howell Synergistic interaction between cisplatin and taxol in human ovarian-carcinoma cells in-vitro Br J Cancer 69 1994 299 306
10. P. Comella, G. Filippelli, G. De Cataldis, B. Massidda, G. Frasci, and L. Maiorino et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) Ann Oncol 18 2007 324 330
11. L.M. Levasseur, W.R. Greco, Y.M. Rustum, and H.K. Slocum Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells Cancer Chemother Pharmacol 40 1997 495 505
12. T. Hayashi, M. Yoshizawa, N. Watanabe, Y. Murayama, and H. Shimizu A case of recurrent gastric cancer effectively treated by combined chemotherapy of weekly paclitaxel (PTX) and CDDP Gan To Kagaku Ryoho Cancer Chemother 33 2006 1167 1169
13. K. Koneri, Y. Hirono, D. Fujimoto, K. Sawai, M. Morikawa, and M. Murakami et al. Five-year survival of alpha-fetoprotein-producing gastric cancer with synchronous liver metastasis: a case report J Gastric Cancer 13 2013 58 64
14. G. Frasci, P. Comella, G. D'Aluto, A. Apicella, R. Thomas, and I. Capasso et al. Cisplatin-epirubicin-paclitaxel (PET) weekly administration with G-CSF support in advanced breast cancer (ABC). A phase II study Eur J Cancer 35 1999 S318
15. G. Frasci, G. D'Aiuto, P. Comella, A. Apicella, R. Thomas, and I. Capasso et al. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group Breast Cancer Res Treat 56 1999 239 252
16. J. Huang, Y. Zhou, H. Zhang, T. Qu, Y. Mao, and H. Zhu et al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy Med Oncol 30 2013 343
17. A.D.S. Merouani, and R.W. Schrier Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone Am J Nephrol 17 1997 53 58
18. V. Lorusso, E. Crucitta, N. Silvestris, G. Rosati, L. Manzione, and M. De Lena et al. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium Oncol Rep 13 2005 283 287
19. P. Hoskins, I. Vergote, A. Cervantes, D. Tu, G. Stuart, and P. Zola et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel J. Natl Cancer Inst. 102 2010 1547 1556
20. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat Nanotechnol 2 2007 751 760
21. M.E. Davis, Z. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat Rev Drug Discovery 7 2008 771 782
22. M. Khan, Z.Y. Ong, N. Wiradharma, A.B.E. Attia, and Y.Y. Yang Advanced materials for co-delivery of drugs and genes in cancer therapy Adv Healthc Mater 1 2012 373 392
23. C.-M.J. Hu, and L. Zhang Nanoparticle-based combination therapy toward overcoming drug resistance in cancer Biochem Pharmacol 83 2012 1104 1111
24. H. Wang, Y. Zhao, Y. Wu, Y.-l. Hu, K. Nan, and G. Nie et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles Biomaterials 32 2011 8281 8290
25. C.E. Soma, C. Dubernet, D. Bentolila, S. Benita, and P. Couvreur Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles Biomaterials 21 2000 1 7
26. G.P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, and K. Marosis et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial Ann Oncol 21 2010 2227 2232
27. H. Xiao, H. Song, Q. Yang, H. Cai, R. Qi, and L. Yan et al. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance Biomaterials 33 2012 6507 6519
28. T.J. Deming Synthetic polypeptides for biomedical applications Prog Polym Sci 32 2007 858 875
29. K. Osada, and K. Kataoka Drug and gene delivery based on supramolecular assembly of PEG-polypeptide hybrid block copolymers Adv Polym Sci 202 2006 113 153
30. W. Qu, S. Chen, S. Ren, X.J. Jiang, R.X. Zhuo, and X.Z. Zhang A bioreducible polypeptide for efficient gene transfection both in vitro and in vivo Chin J Polym Sci 31 2013 713 718
31. W.T. Song, M.Q. Li, Z.H. Tang, Q.S. Li, Y. Yang, and H.Y. Liu et al. Methoxypoly(ethylene glycol)-block-poly(l-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers Macromol Biosci 12 2012 1514 1523
32. H.Y. Tian, C. Deng, H. Lin, J.R. Sun, M.X. Deng, and X.S. Chen et al. Biodegradable cationic PEG-PEI-PBLG hyperbranched block copolymer: synthesis and micelle characterization Biomaterials 26 2005 4209 4217
33. C. Deng, X.S. Chen, H.J. Yu, J. Sun, T.C. Lu, and X.B. Jing A biodegradable triblock copolymer poly(ethylene glycol)-b-poly(l-lactide)-b- poly(l-lysine): synthesis, self-assembly and RGD peptide modification Polymer 48 2007 139 149
34. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 2006 621 681
35. J. Dai, S.D. Lin, D. Cheng, S.Y. Zou, and X.T. Shuai Interlayer- crosslinked micelle with partially hydrated core showing reduction and pH Dual sensitivity for pinpointed intracellular drug release Angew Chem Int Ed 50 2011 9404 9408
36. A.N. Koo, K.H. Min, H.J. Lee, S.-U. Lee, K. Kim, and I.C. Kwon et al. Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links Biomaterials 33 2012 1489 1499
37. K. Xiao, Y. Li, J. Luo, J.S. Lee, W. Xiao, and A.M. Gonik et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles Biomaterials 32 2011 3435 3446
38. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, and Y. Sugiyama et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res 63 2003 8977 8983
39. G. Le The pH difference between tumor and normal tissue offers a tumor specific target for the treatment of cancer Drug Resist Updates 3 2000 49 50
40. E.K. Rowinsky, M.R. Gilbert, W.P. Mcguire, D.A. Noe, L.B. Grochow, and A.A. Forastiere et al. Sequences of taxol and cisplatin - a phase-I and pharmacological study J Clin Oncol 9 1991 1692 1703
41. P.L. Judson, J.M. Watson, P.A. Gehrig, W.C. Fowler, and J.S. Haskill Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy Cancer Res 59 1999 2425 2432
42. A. Bressenot, S. Marchal, L. Bezdetnaya, J. Garrier, F. Guillemin, and F. Plenat Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma J Histochem Cytochem 57 2009 289 300
43. C.L. Fu, L. Lin, H.L. Shi, D.X. Zheng, W. Wang, and S.Q. Gao et al. Hydrophobic poly (amino acid) modified PEI mediated delivery of rev-casp-3 for cancer therapy Biomaterials 33 2012 4589 4596